Medical Revenue Cycle Management in Houston

Medical revenue cycle management covers the financial workflow from referral and eligibility verification through documentation, coding, authorization, claim submission, payment posting, denial resolution, and A/R follow-up. For infectious disease practices, the process may also include infusion administration, OPAT, specialty drugs, hospital consults, and coverage agreements. A specialized approach helps connect clinical workflows with reimbursement requirements.

Infectious disease practices often manage cognitive services alongside infusion, OPAT, drug acquisition, and hospital-related work. Claims may involve different benefit structures, authorization requirements, documentation expectations, units, NDC information, and payer contract terms. Revenue can be delayed or missed when those elements are not coordinated across clinical, coding, front-office, and billing workflows.

Yes. The service catalog addresses infusion and OPAT workflows across eligibility, benefit determination, prior authorization, drug and administration billing, claims submission, denials, payment review, and A/R follow-up. The goal is to help practices examine the complete path from referral to first dose and final payment while identifying gaps that may leave drug or administration revenue uncollected.

Revenue leakage can occur through under-leveled visits, missed drug or administration charges, incomplete documentation, authorization gaps, unpursued balances, contract discrepancies, and claims that stall in A/R. Reporting by payer, service line, and provider can reveal denial patterns, payment trends, and missing revenue. The analysis then traces each issue back to documentation, charge capture, workflow, or contract causes.

Denial management starts by categorizing denials according to their underlying cause, such as drug and administration coding, missing authorization, medical versus pharmacy benefit confusion, or under-documented consults. Appeals can then be prepared around payer requirements and clinical documentation. Findings should also return to clinical, coding, and front-office teams so recurring denial patterns can be addressed.

Payment reconciliation compares payments with expected reimbursement for drug, administration, and E/M claims. The review can flag short-pays, incorrect fee schedule application, unit mismatches, and NDC-related issues. Contract and coverage agreement reviews can also help practices assess whether payment aligns with documented terms, including arrangements involving hospital coverage or stewardship work.

The resources are intended for infectious disease physicians, independent infectious disease practices, infectious disease group leaders, and medical practice administrators. They can support practices evaluating revenue streams, launching or reviewing infusion and OPAT services, adding providers, examining workflow performance, or investigating why collections do not appear to match the work being delivered.

No. GrowInfectiousDisease does not publish invented rates, benchmarks, drug acquisition costs, payment rates, or margin figures. The tools and guidance are designed to help practices apply their own numbers and distinguish verified information from unknown or practice-specific figures. This supports a more transparent evaluation of revenue-cycle performance and financial sustainability.